Vaccines,
Год журнала:
2024,
Номер
12(10), С. 1161 - 1161
Опубликована: Окт. 11, 2024
Background:
Self-amplifying
mRNA
vaccines
have
the
potential
to
increase
magnitude
and
duration
of
protection
against
COVID-19
by
boosting
neutralizing
antibody
titers
cellular
responses.
Methods:
In
this
study,
we
used
immunogenicity
data
from
a
phase
3
randomized
trial
comparing
ARCT-154,
self-amplifying
vaccine,
with
BNT162b2
vaccine
estimate
relative
efficacy
(rVE)
two
over
time
in
younger
(<60
years)
older
(≥60
adults.
Results:
By
day
181
post-vaccination,
rVE
symptomatic
severe
Wuhan-Hu-1
disease
was
9.2–11.0%
1.2–1.5%,
respectively,
across
age
groups
whereas
Omicron
BA.4/5
26.8–48.0%
5.2–9.3%,
groups.
Sensitivity
analysis
showed
that
varying
threshold
titer
for
50%
up
10%
convalescent
sera
revealed
incremental
benefits
ARCT-154
BNT162b2,
an
28.0%
adults
aged
≥60
year.
Conclusions:
Overall,
results
study
indicate
elicits
broader
more
durable
SARS-CoV-2,
translating
enhanced
protection,
particularly
BA.4/5.
Nature Communications,
Год журнала:
2025,
Номер
16(1)
Опубликована: Янв. 7, 2025
Self-replicating
RNA
(srRNA)
technology,
in
comparison
to
mRNA
vaccines,
has
shown
dose-sparing
by
approximately
10-fold
and
more
durable
immune
responses.
However,
no
improvements
are
observed
the
adverse
events
profile.
Here,
we
develop
an
srRNA
vaccine
platform
with
optimized
non-coding
regions
demonstrate
immunogenicity
safety
preclinical
clinical
development.
Optimized
vaccines
generate
protective
immunity
(according
WHO
defined
thresholds)
at
doses
up
1,000,000-fold
lower
than
female
mouse
models
of
influenza
rabies.
Clinically,
RBI-4000,
vector
encoding
rabies
glycoprotein,
was
evaluated
a
Phase
I
study
(NCT06048770).
RBI-4000
able
elicit
de
novo
majority
healthy
participants
when
administered
dose
0.1,
1,
or
10
microgram
(71%,
94%,
100%,
respectively)
prime-boost
schedule.
Similarly,
observe
above
benchmark
protection
following
single
administration
most
both
1
doses.
There
serious
reported
across
all
cohorts.
These
data
establish
high
therapeutic
index
vectors,
demonstrating
feasibility
low
approaches
for
applications.
Here
authors
report
self-replicating
approach
that
generates
much
mice.
In
using
glycoprotein
as
antigen,
they
show
robust
responses
0.1
µg,
favorable
Advanced Science,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 23, 2024
Abstract
The
efficacy
and
safety
of
self‐amplifying
mRNA
(saRNA)
have
been
demonstrated
in
COVID‐19
vaccine
applications.
Unlike
conventional
non‐replicating
(nrmRNA),
saRNA
offers
a
key
advantage:
its
self‐replication
mechanism
fosters
efficient
expression
the
encoded
protein,
leading
to
substantial
dose
savings
during
administration.
Consequently,
there
is
growing
interest
further
optimizing
efficiency
saRNA.
In
this
study,
vitro
adaptive
passaging
conducted
under
exogenous
interferon
pressure,
which
revealed
several
mutations
nonstructural
protein
(NSP).
Notably,
two
stable
mutations,
Q48P
I113F,
situated
NSP3
macrodomain
(MD),
attenuated
mono
adenosine
diphosphate
ribose
(MAR)
hydrolysis
activity
exhibited
decreased
replication
but
increased
payload
compared
wild‐type
(wt
saRNA).
Transcriptome
sequencing
analysis
unveils
diminished
activation
double‐stranded
RNA
(dsRNA)
sensor
and,
consequently,
significantly
reduced
innate
immune
response
wt
Furthermore,
mutant
less
translation
inhibition
cell
apoptosis
than
saRNA,
culminating
higher
both
vivo.
These
findings
underscore
potential
reducing
replication‐dependent
dsRNA‐induced
responses
through
genetic
modification
as
valuable
strategy
for
enhancing
efficiency,
mitigating
cytotoxicity.
BACKGROUND
The
COVID-19
pandemic
has
exposed
the
vulnerabilities
of
global
supply
chains
(SC),
particularly
within
healthcare
sector,
underscoring
need
for
advanced
methods
to
enhance
SC
resilience
and
sustainability.
Pandemics,
such
as
Influenza,
pose
considerable
risks
chain
(HSC)
performance,
demanding
robust
analytical
tools
optimize
system
efficiency
under
uncertain
conditions.
OBJECTIVE
In
this
paper,
we
map
current
literature
synthesize
insights
on
role
leadership
in
driving
Artificial
Intelligence
(AI)-driven
approaches
enhancing
HSC
organizations.
This
systematic
review
aims
HSC-resilience
(HSCR)
apply
a
novel
network
range
directional
measure
model
evaluate
sustainability
response
pandemic.
METHODS
followed
PRISMA
guidelines,
encompassing
multiple
databases,
including
Business
Source
Premier,
CINAHL,
ACM
Digital
Library,
MEDLINE,
PsycINFO,
Web
Science,
PubMed,
ScienceDirect.
targeted
articles
published
from
2016
2024,
focusing
empirical
studies.
A
predetermined
search
strategy
used
keywords
resilience,
artificial
intelligence,
healthcare,
related
terms.
analysis
involved
an
inductive,
thematic
approach
qualitatively
evidence.
screening
data
extraction
processes
were
independently
carried
out
by
two
reviewers,
with
Cohen's
kappa
assess
interrater
agreement.
Data
synthesis
was
accomplished
through
narrative
approach.
RESULTS
comprehensive
case
study
demonstrates
practical
application
model,
revealing
its
capability
diverse
findings
highlight
how
decision-making
unit
varies
changing
circumstances,
showcasing
model’s
robustness
evaluating
performance
during
disruptions.
final
number
studies
included
39.
These
clinical
units
quantitative
qualitative
decision
support
models
16/39
(41%)
25/39
(59%),
respectively.
earliest
article
2018;
most
recent
2022.
CONCLUSIONS
is
one
first
compare
AI
conventional
human
real-time
gathering
AI-driven
strategies
strengthen
HSC.
While
proves
effective
assessing
sustainability,
key
limitation
lies
implementation
methodologies
Future
research
should
focus
real-world
deployment
these
face
potential
Biotechnology Journal,
Год журнала:
2025,
Номер
20(2)
Опубликована: Фев. 1, 2025
The
full
approval
of
two
SARS-CoV-2
mRNA
vaccines,
Comirnaty
and
Spikevax,
has
greatly
accelerated
the
development
numerous
vaccine
candidates
targeting
infectious
diseases
cancer.
vaccines
provide
a
rapid,
safe,
versatile
manufacturing
process
while
eliciting
strong
humoral
cellular
immune
responses,
making
them
particularly
beneficial
for
addressing
emerging
pandemics.
Recent
advancements
in
modified
nucleotides
lipid
nanoparticle
delivery
systems
have
further
emphasized
potential
this
platform.
Despite
these
transformative
opportunities,
significant
improvements
are
needed
to
enhance
efficacy,
stability,
immunogenicity.
This
review
outlines
fundamentals
design,
process,
administration
strategies,
along
with
various
optimization
approaches.
It
also
offers
comprehensive
overview
developed
since
onset
COVID-19
pandemic,
challenges
posed
by
variants,
current
strategies
address
variants.
Finally,
we
discuss
broad-spectrum
combined
examine
future
prospects
Self-amplifying
RNA
(saRNA)
has
the
potential
to
provide
durable,
non-integrative
transgene
expression
for
transient
gene
therapy.
However,
its
auto-replicative
nature
mimics
viral
infection,
triggering
innate
immune
responses
that
shutdown
cap-dependent
translation,
degrade
cellular
mRNA,
induce
cell
death,
and
release
cytokines.
In
non-immunotherapy
applications,
this
activation
is
undesirable
as
it
limits
expression,
depletes
transfected
cells,
induces
inflammation,
undermining
therapeutic
outcomes.
Moreover,
use
of
exogenous
suppressants
mitigate
these
effects
often
increases
treatment
complexity
risk
unintended
systemic
side
effects.
To
address
challenges,
we
developed
a
strategy
encode
broad-spectrum
suppression
directly
within
saRNA.
This
approach
leverages
cap-independent
translation
bypass
saRNA-triggered
shutdown,
enabling
multiple
inhibitors
targeting
diverse
double-stranded
RNA-sensing
inflammatory
signaling
pathways.
mouse
primary
fibroblast-like
synoviocytes—a
type
relevant
joint
diseases—this
eliminates
need
external
inhibitors,
reduces
cytotoxicity
antiviral
cytokine
secretion,
enables
sustained
can
be
controlled
with
small-molecule
antiviral.
These
findings
support
development
saRNA
therapeutics
offer
non-integrative,
externally
controllable
without
persistent
or
reliance
on
suppressants.
Self-amplifying
RNA
(saRNA)
has
the
potential
to
provide
durable,
non-integrative
transgene
expression
for
transient
gene
therapy.
However,
its
auto-replicative
nature
mimics
viral
infection,
triggering
innate
immune
responses
that
shutdown
cap-dependent
translation,
degrade
cellular
mRNA,
induce
cell
death,
and
release
cytokines.
In
non-immunotherapy
applications,
this
activation
is
undesirable
as
it
limits
expression,
depletes
transfected
cells,
induces
inflammation,
undermining
therapeutic
outcomes.
Moreover,
use
of
exogenous
suppressants
mitigate
these
effects
often
increases
treatment
complexity
risk
unintended
systemic
side
effects.
To
address
challenges,
we
developed
a
strategy
encode
broad-spectrum
suppression
directly
within
saRNA.
This
approach
leverages
cap-independent
translation
bypass
saRNA-triggered
shutdown,
enabling
multiple
inhibitors
targeting
diverse
double-stranded
RNA-sensing
inflammatory
signaling
pathways.
mouse
primary
fibroblast-like
synoviocytes—a
type
relevant
joint
diseases—this
eliminates
need
external
inhibitors,
reduces
cytotoxicity
antiviral
cytokine
secretion,
enables
sustained
can
be
controlled
with
small-molecule
antiviral.
These
findings
support
development
saRNA
therapeutics
offer
non-integrative,
externally
controllable
without
persistent
or
reliance
on
suppressants.